---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-193945"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:02:36.857745+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharma Q1 net rev $58.3M (+104% YoY); maintains FY 2026 op profitability guidance

## Summary
- Q1 net revenues $58.3M vs $28.5M YoY; net loss $30.4M vs $94.3M YoY.
- Non-GAAP operating expenses $56.2M, down ~43% YoY; cash and equivalents $180.9M.
- ~1.35M total VOQUEZNA prescriptions filled to date; Q1 covered prescriptions up 91% YoY.
- FY 2026 guidance: net rev $320-345M, non-GAAP op ex $235-255M; op profitability expected Q3 2026.
- EoE phase 2 trial (pHalcon-EoE-201) topline results expected late Q4 2026/early Q1 2027.

## SEC filing metadata
- accession: 0001193125-26-193945
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/0001193125-26-193945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/d140332d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-193945
- JSON: https://secwatch.observer/filing/0001193125-26-193945.json
- Plain text: https://secwatch.observer/filing/0001193125-26-193945.txt

## Key facts
- Earnings Releases
  Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $58.3 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $58.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update • ~1.35 million total VOQUEZNA ® prescriptions filled to date • $58.3 million in Q1 net revenues, a 104% increase year-over-year • Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/0001193125-26-193945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.